Robert B Clarke

List of Publications by Year
in descending order

162 papers	13,752 citations	22153 59 h-index	22166 113 g-index
181 all docs	181 docs citations	181 times ranked	19187 citing authors

#	Article	IF	Citations
1	Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research. Cancer Discovery, 2014, 4, 998-1013.	9.4	1,341
2	Interrogating open issues in cancer precision medicine with patient-derived xenografts. Nature Reviews Cancer, 2017, 17, 254-268.	28.4	527
3	Aberrant Activation of Notch Signaling in Human Breast Cancer. Cancer Research, 2006, 66, 1517-1525.	0.9	515
4	The properties of high-dimensional data spaces: implications for exploring gene and protein expression data. Nature Reviews Cancer, 2008, 8, 37-49.	28.4	483
5	Regulation of Breast Cancer Stem Cell Activity by Signaling through the Notch4 Receptor. Cancer Research, 2010, 70, 709-718.	0.9	468
6	Identification of a putative intestinal stem cell and early lineage marker; musashi-1. Differentiation, 2003, 71, 28-41.	1.9	442
7	Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling. Oncogene, 2003, 22, 7316-7339.	5.9	421
8	Mammary Stem Cells and Breast Cancerâ€"Role of Notch Signalling. Stem Cell Reviews and Reports, 2007, 3, 169-175.	5.6	342
9	Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. Breast Cancer Research, 2013, 15, R92.	5.0	320
10	A putative human breast stem cell population is enriched for steroid receptor-positive cells. Developmental Biology, 2005, 277, 443-456.	2.0	312
11	A Detailed Mammosphere Assay Protocol for the Quantification of Breast Stem Cell Activity. Journal of Mammary Gland Biology and Neoplasia, 2012, 17, 111-117.	2.7	299
12	Novel Cell Culture Technique for Primary Ductal Carcinoma In Situ: Role of Notch and Epidermal Growth Factor Receptor Signaling Pathways. Journal of the National Cancer Institute, 2007, 99, 616-627.	6.3	288
13	Endocrine resistance in breast cancer â€“ An overview and update. Molecular and Cellular Endocrinology, 2015, 418, 220-234.	3.2	280
14	Risk determination and prevention of breast cancer. Breast Cancer Research, 2014, 16, 446.	5.0	248
15	Estrogen Receptor-Positive Proliferating Cells in the Normal and Precancerous Breast. American Journal of Pathology, 1999, 155, 1811-1815.	3.8	247
16	Estrogen sensitivity of normal human breast tissue in vivo and implanted into athymic nude mice: Analysis of the relationship between estrogen-induced proliferation and progesterone receptor expression. Breast Cancer Research and Treatment, 1997, 45, 121-133.	2.5	235
17	Recent advances reveal IL-8 signaling as a potential key to targeting breast cancer stem cells. Breast Cancer Research, 2013, 15, 210.	5.0	203
18	Patient-derived xenograft (PDX) models in basic and translational breast cancer research. Cancer and Metastasis Reviews, 2016, 35, 547-573.	5.9	189

#	Article	IF	Citations
19	Targeting CXCR1/2 Significantly Reduces Breast Cancer Stem Cell Activity and Increases the Efficacy of Inhibiting HER2 via HER2-Dependent and -Independent Mechanisms. Clinical Cancer Research, 2013, 19, 643-656.	7.0	184
20	Endoplasmic Reticulum Stress, the Unfolded Protein Response, Autophagy, and the Integrated Regulation of Breast Cancer Cell Fate. Cancer Research, 2012, 72, 1321-1331.	0.9	183
21	The Centrosomal Kinase Nek2 Displays Elevated Levels of Protein Expression in Human Breast Cancer. Cancer Research, 2004, 64, 7370-7376.	0.9	167
22	Anti-estrogen Resistance in Human Breast Tumors Is Driven by JAG1-NOTCH4-Dependent Cancer Stem Cell Activity. Cell Reports, 2015, 12, 1968-1977.	6.4	164
23	Estrogen responsiveness and control of normal human breast proliferation. Journal of Mammary Gland Biology and Neoplasia, 1998, 3, 23-35.	2.7	157
24	Origins of breast cancer subtypes and therapeutic implications. Nature Clinical Practice Oncology, 2007, 4, 516-525.	4.3	155
25	The removal of multiplicative, systematic bias allows integration of breast cancer gene expression datasets â€“ improving meta-analysis and prediction of prognosis. BMC Medical Genomics, 2008, 1, 42.	1.5	134
26	Steroid Receptors and Cell Cycle in Normal Mammary Epithelium. Journal of Mammary Gland Biology and Neoplasia, 2004, 9, 3-13.	2.7	129
27	Hormonal aspects of breast cancer. Critical Reviews in Oncology/Hematology, 1992, 12, 1-23.	4.4	128
28	Wnt Pathway Activity in Breast Cancer Sub-Types and Stem-Like Cells. PLoS ONE, 2013, 8, e67811.	2.5	126
29	Reduction in apoptosis relative to mitosis in histologically normal epithelium accompanies fibrocystic change and carcinoma of the premenopausal human breast. Journal of Pathology, 1992, 167, 25-32.	4.5	120
30	Human breast cancer cell line xenografts as models of breast cancer â€” The immunobiologies of recipient mice and the characteristics of several tumorigenic cell lines. Breast Cancer Research and Treatment, 1996, 39, 69-86.	2.5	114
31	Regulation of human breast epithelial stem cells. Cell Proliferation, 2003, 36, 45-58.	5.3	109
32	Microenvironmental IL1Î² promotes breast cancer metastatic colonisation in the bone via activation of Wnt signalling. Nature Communications, 2019, 10, 5016.	12.8	105
33	Induction of apoptosis by tamoxifen and ICI 182780 in primary breast cancer. , 1997, 72, 608-613.		104
34	Doxycycline down-regulates DNA-PK and radiosensitizes tumor initiating cells: Implications for more effective radiation therapy. Oncotarget, 2015, 6, 14005-14025.	1.8	103
35	The Mammary Gland â€œSide Populationâ€• A Putative Stem/Progenitor Cell Marker?. Journal of Mammary Gland Biology and Neoplasia, 2005, 10, 37-47.	2.7	101
36	Effect of tamoxifen on Ki67 labelling index in human breast tumours and its relationship to oestrogen and progesterone receptor status. British Journal of Cancer, 1993, 67, 606-611.	6.4	100

#	Article	IF	Citations
37	Multifunctionalized iron oxide nanoparticles for selective drug delivery to CD44-positive cancer cells. Nanotechnology, 2016, 27, 065103.	2.6	100
38	Type I insulin-like growth factor receptor gene expression in normal human breast tissue treated with oestrogen and progesterone. British Journal of Cancer, 1997, 75, 251-257.	6.4	89
39	The Embryonic Transcription Cofactor LBH Is a Direct Target of the Wnt Signaling Pathway in Epithelial Development and in Aggressive Basal Subtype Breast Cancers. Molecular and Cellular Biology, 2010, 30, 4267-4279.	2.3	82
40	Oestrogen increases the activity of oestrogen receptor negative breast cancer stem cells through paracrine EGFR and Notch signalling. Breast Cancer Research, 2013, 15, R21.	5.0	82
41	Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy. Breast Cancer Research and Treatment, 2011, 125, 279-287.	2.5	80
42	NF-Î¹B Signaling Is Required for XBP1 (Unspliced and Spliced)-Mediated Effects on Antiestrogen Responsiveness and Cell Fate Decisions in Breast Cancer. Molecular and Cellular Biology, 2015, 35, 379-390.	2.3	80
43	Knockdown of estrogen receptorâ€Î± induces autophagy and inhibits antiestrogenâ€mediated unfolded protein response activation, promoting ROSâ€induced breast cancer cell death. FASEB Journal, 2014, 28, 3891-3905.	0.5	78
44	Antiestrogens, Aromatase Inhibitors, and Apoptosis in Breast Cancer. Vitamins and Hormones, 2005, 71, 201-237.	1.7	75
45	Stem cells in breast tumours: Are they ready for the clinic?. European Journal of Cancer, 2012, 48, 2104-2116.	2.8	75
46	Breast Cancer Stem Cells: Something Out of Notching?. Cancer Research, 2010, 70, 8973-8976.	0.9	74
47	Leptin as a mediator of tumor-stromal interactions promotes breast cancer stem cell activity. Oncotarget, 2016, 7, 1262-1275.	1.8	74
48	Steroid receptors in human breast cancer. Trends in Endocrinology and Metabolism, 2004, 15, 316-323.	7.1	73
49	Gene network signaling in hormone responsiveness modifies apoptosis and autophagy in breast cancer cells. Journal of Steroid Biochemistry and Molecular Biology, 2009, 114, 8-20.	2.5	73
50	Targeting inhibitor of apoptosis proteins in combination with ErbB antagonists in breast cancer. Breast Cancer Research, 2009, 11, R41.	5.0	72
51	Steroid receptors and proliferation in the human breast. Steroids, 2003, 68, 789-794.	1.8	71
52	Identification and functional analysis of SKA2 interaction with the glucocorticoid receptor. Journal of Endocrinology, 2008, 198, 499-509.	2.6	71
53	Effects of oestrogen on gene expression in epithelium and stroma of normal human breast tissue. Endocrine-Related Cancer, 2006, 13, 617-628.	3.1	69
54	Isolation and characterization of human mammary stem cells. Cell Proliferation, 2005, 38, 375-386.	5.3	67

#	Article	IF	Citations
55	Cell cycle regulators cyclin D1 and CDK4/6 have estrogen receptor-dependent divergent functions in breast cancer migration and stem cell-like activity. Cell Cycle, 2013, 12, 2384-2394.	2.6	67
56	Activated c-SRC in ductal carcinoma in situ correlates with high tumour grade, high proliferation and HER2 positivity. British Journal of Cancer, 2006, 95, 1410-1414.	6.4	66
57	Pâ€Cadherin Is Coexpressed with CD44 and CD49f and Mediates Stem Cell Properties in Basalâ€like Breast Cancer. Stem Cells, 2012, 30, 854-864.	3.2	64
58	Targeting Treatment-Resistant Breast Cancer Stem Cells with FKBPL and Its Peptide Derivative, AD-01, via the CD44 Pathway. Clinical Cancer Research, 2013, 19, 3881-3893.	7.0	63
59	Abnormal regulation of the oestrogen receptor in benign breast lesions. Journal of Clinical Pathology, 2000, 53, 778-783.	2.0	61
60	Cisplatin selects for stem-like cells in osteosarcoma by activating Notch signaling. Oncotarget, 2016, 7, 33055-33068.	1.8	60
61	GPER mediates the angiocrine actions induced by IGF1 through the HIF-1Î±/VEGF pathway in the breast tumor microenvironment. Breast Cancer Research, 2017, 19, 129.	5.0	59
62	Contrasting Hypoxic Effects on Breast Cancer Stem Cell Hierarchy Is Dependent on ER-Î± Status. Cancer Research, 2013, 73, 1420-1433.	0.9	56
63	Animal models of breast cancer: Their diversity and role in biomedical research. Breast Cancer Research and Treatment, 1996, 39, 1-6.	2.5	55
64	Prolactin receptor antagonism reduces the clonogenic capacity of breast cancer cells and potentiates doxorubicin and paclitaxel cytotoxicity. Breast Cancer Research, 2008, 10, R68.	5.0	55
65	Focal Adhesion Kinase and Wnt Signaling Regulate Human Ductal Carcinoma In Situ Stem Cell Activity and Response to Radiotherapy. Stem Cells, 2015, 33, 327-341.	3.2	55
66	Resistance to Endocrine Therapy: Are Breast Cancer Stem Cells the Culprits?. Journal of Mammary Gland Biology and Neoplasia, 2009, 14, 45-54.	2.7	54
67	Breast Cancer Stem Cells and Their Role in Resistance to Endocrine Therapy. Hormones and Cancer, 2011, 2, 91-103.	4.9	54
68	A differential role for CXCR4 in the regulation of normal versus malignant breast stem cell activity. Oncotarget, 2014, 5, 599-612.	1.8	53
69	Issues in experimental design and endpoint analysis in the study of experimental cytotoxic agents in vivo in breast cancer and other models. Breast Cancer Research and Treatment, 1997, 46, 255-278.	2.5	52
70	An integrated genomic approach identifies that the PI3K/AKT/FOXO pathway is involved in breast cancer tumor initiation. Oncotarget, 2016, 7, 2596-2610.	1.8	52
71	Do estrogens always increase breast cancer risk?. Journal of Steroid Biochemistry and Molecular Biology, 2002, 80, 163-174.	2.5	51
72	Application of Metabolomics in Drug Resistant Breast Cancer Research. Metabolites, 2015, 5, 100-118.	2.9	50

#	Article	IF	Citations
73	A Role for Notch Signalling in Breast Cancer and Endocrine Resistance. Stem Cells International, 2016, 2016, 1-6.	2.5	50
74	Endoplasmic reticulum stress, the unfolded protein response, and gene network modeling in antiestrogen resistant breast cancer. Hormone Molecular Biology and Clinical Investigation, 2011, 5, 35-44.	0.7	49
75	P-cadherin signals through the laminin receptor Î±6Î²4 integrin to induce stem cell and invasive properties in basal-like breast cancer cells. Oncotarget, 2014, 5, 679-692.	1.8	49
76	Analysis of tyrosine kinase mRNAs including four FGF receptor mRNAs expressed in MCF-7 breast-cancer cells. International Journal of Cancer, 1992, 50, 598-603.	5.1	47
77	Ovarian steroids and the human breast: Regulation of stem cells and cell proliferation. Maturitas, 2006, 54, 327-334.	2.4	46
78	Human breast epithelial stem cells and their regulation. Journal of Pathology, 2006, 208, 7-16.	4.5	46
79	FKBPL and its peptide derivatives inhibit endocrine therapy resistant cancer stem cells and breast cancer metastasis by downregulating DLL4 and Notch4. BMC Cancer, 2019, 19, 351.	2.6	45
80	Effects of short-term antiestrogen treatment of primary breast cancer on estrogen receptor mRNA and protein expression and on estrogen-regulated genes. Breast Cancer Research and Treatment, 1996, 41, 31-41.	2.5	42
81	Human breast cell proliferation and its relationship to steroid receptor expression. Climacteric, 2004, 7, 129-137.	2.4	42
82	Biomarkers of Dietary Energy Restriction in Women at Increased Risk of Breast Cancer. Cancer Prevention Research, 2009, 2, 720-731.	1.5	41
83	SPRY1 regulates mammary epithelial morphogenesis by modulating EGFR-dependent stromal paracrine signaling and ECM remodeling. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E5731-40.	7.1	41
84	Dissecting tumor metabolic heterogeneity: Telomerase and large cell size metabolically define a sub-population of stem-like, mitochondrial-rich, cancer cells. Oncotarget, 2015, 6, 21892-21905.	1.8	41
85	Patient-derived Mammosphere and Xenograft Tumour Initiation Correlates with Progression to Metastasis. Journal of Mammary Gland Biology and Neoplasia, 2016, 21, 99-109.	2.7	40
86	Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification. Cancer Research, 2022, 82, 1646-1657.	0.9	40
87	Combined Inhibition of ErbB1/2 and Notch Receptors Effectively Targets Breast Ductal Carcinoma In Situ (DCIS) Stem/Progenitor Cell Activity Regardless of ErbB2 Status. PLoS ONE, 2013, 8, e56840.	2.5	37
88	Intermittent energy restriction induces changes in breast gene expression and systemic metabolism. Breast Cancer Research, 2016, 18, 57.	5.0	37
89	p27KIP1phosphorylation by PKB/Akt leads to poor breast cancer prognosis. Breast Cancer Research, 2003, 5, 162-3.	5.0	36
90	Disruption of a Quorum Sensing mechanism triggers tumorigenesis: a simple discrete model corroborated by experiments in mammary cancer stem cells. Biology Direct, 2010, 5, 20.	4.6	36

#	Article	IF	Citations
91	Tumourâ€promoting activity of altered WWP1 expression in breast cancer and its utility as a prognostic indicator. Journal of Pathology, 2008, 216, 93-102.	4.5	35
92	The role of steroid hormones in breast cancer stem cells. Endocrine-Related Cancer, 2015, 22, T177-T186.	3.1	35
93	Targeting IL-8 signalling to inhibit breast cancer stem cell activity. Expert Opinion on Therapeutic Targets, 2013, 17, 1235-1241.	3.4	34
94	Time-resolved single-cell analysis of Brca1 associated mammary tumourigenesis reveals aberrant differentiation of luminal progenitors. Nature Communications, 2021, 12, 1502.	12.8	34
95	Enrichment of human osteosarcoma stem cells based on hTERT transcriptional activity. Oncotarget, 2013, 4, 2326-2338.	1.8	33
96	Acquired Resistance of ER-Positive Breast Cancer to Endocrine Treatment Confers an Adaptive Sensitivity to TRAIL through Posttranslational Downregulation of c-FLIP. Clinical Cancer Research, 2018, 24, 2452-2463.	7.0	32
97	Development of clinically relevant in vivo metastasis models using human bone discs and breast cancer patient-derived xenografts. Breast Cancer Research, 2019, 21, 130.	5.0	32
98	The Biology of Breast Tumor Progression: Acquisition of hormone independence and resistance to cytotoxic drugs. Acta OncolÃ³gica, 1992, 31, 115-123.	1.8	31
99	Mechanisms of Disease: prediction and prevention of breast cancerâ€"cellular and molecular interactions. Nature Clinical Practice Oncology, 2005, 2, 635-646.	4.3	29
100	The Role of Steroid Hormones in Breast and Effects on Cancer Stem Cells. Current Stem Cell Reports, 2018, 4, 81-94.	1.6	29
101	High-throughput genomic technology in research and clinical management of breast cancer. Exploiting the potential of gene expression profiling: is it ready for the clinic?. Breast Cancer Research, 2006, 8, 214.	5.0	28
102	Dickkopf1 Regulates Fate Decision and Drives Breast Cancer Stem Cells to Differentiation: An Experimentally Supported Mathematical Model. PLoS ONE, 2011, 6, e24225.	2.5	28
103	Where do selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs) now fit into breast cancer treatment algorithms?. Journal of Steroid Biochemistry and Molecular Biology, 2001, 79, 227-237.	2.5	27
104	G Protein-Coupled Receptors at the Crossroad between Physiologic and Pathologic Angiogenesis: Old Paradigms and Emerging Concepts. International Journal of Molecular Sciences, 2017, 18, 2713.	4.1	27
105	Targeting Endometrial Cancer Stem Cell Activity with Metformin Is Inhibited by Patient-Derived Adipocyte-Secreted Factors. Cancers, 2019, 11, 653.	3.7	27
106	The Notch Pathway Promotes Osteosarcoma Progression through Activation of Ephrin Reverse Signaling. Molecular Cancer Research, 2019, 17, 2383-2394.	3.4	27
107	Targeting STAT3 signaling using stabilised sulforaphane (SFX-01) inhibits endocrine resistant stem-like cells in ER-positive breast cancer. Oncogene, 2020, 39, 4896-4908.	5.9	27
108	Effect of a farnesyl transferase inhibitor (R115777) on ductal carcinoma in situ of the breast in a human xenograft model and on breast and ovarian cancer cell growth in vitro and in vivo. Breast Cancer Research, 2006, 8, R21.	5.0	25

#	Article	IF	Citations
109	Effects of oestrogens and anti-oestrogens on normal breast tissue from women bearing BRCA1 and BRCA2 mutations. British Journal of Cancer, 2006, 94, 1021-1028.	6.4	24
110	Increased Expression of Interleukin-1 Receptor Characterizes Anti-estrogen-Resistant ALDH+ Breast Cancer Stem Cells. Stem Cell Reports, 2020, 15, 307-316.	4.8	24
111	Animal models of breast cancer: experimental design and their use in nutrition and psychosocial research. Breast Cancer Research and Treatment, 1997, 46, 117-133.	2.5	22
112	Combining Notch inhibition with current therapies for breast cancer treatment. Therapeutic Advances in Medical Oncology, 2013, 5, 17-24.	3.2	21
113	Regulation of the nuclear localization of the human Nedd4-related WWP1 protein by Notch. Molecular Membrane Biology, 2006, 23, 269-276.	2.0	20
114	Changes in the normal human breast throughout the menstrual cycle: relevance to breast carcinogenesis. Endocrine-Related Cancer, 1997, 4, 23-33.	3.1	18
115	Lapatinib inhibits stem/progenitor proliferation in preclinical in vitro models of ductal carcinoma in situ (DCIS). Cell Cycle, 2014, 13, 418-425.	2.6	18
116	PAK4 regulates stemness and progression in endocrine resistant ER-positive metastatic breast cancer. Cancer Letters, 2019, 458, 66-75.	7.2	18
117	FAK inhibition alone or in combination with adjuvant therapies reduces cancer stem cell activity. Npj Breast Cancer, 2021, 7, 65.	5.2	17
118	Hormone dependence of breast cancer cells and the effects of tamoxifen and estrogen:31P NMR studies. Breast Cancer Research and Treatment, 1995, 33, 209-217.	2.5	16
119	Tissue Factor promotes breast cancer stem cell activity in vitro. Oncotarget, 2017, 8, 25915-25927.	1.8	16
120	Oestrogens, Beatson and endocrine therapy. Endocrine-Related Cancer, 1997, 4, 371-380.	3.1	15
121	Estrogen-Induced Apoptosis in Breast Cancers Is Phenocopied by Blocking Dephosphorylation of Eukaryotic Initiation Factor 2 Alpha (eIF2Î±) Protein. Molecular Cancer Research, 2019, 17, 918-928.	3.4	15
122	Co-ordination of cell cycle, migration and stem cell-like activity in breast cancer. Oncotarget, 2014, 5, 7833-7842.	1.8	15
123	Systems biology: perspectives on multiscale modeling in research on endocrine-related cancers. Endocrine-Related Cancer, 2019, 26, R345-R368.	3.1	14
124	Introduction and overview: sex steroids in the mammary gland. Journal of Mammary Gland Biology and Neoplasia, 2000, 5, 245-250.	2.7	13
125	Tailored Functionalized Magnetic Nanoparticles to Target Breast Cancer Cells Including Cancer Stem-Like Cells. Cancers, 2020, 12, 1397.	3.7	13
126	TPD52 and NFKB1 gene expression levels correlate with G2 chromosomal radiosensitivity in lymphocytes of women with and at risk of hereditary breast cancer. International Journal of Radiation Biology, 2007, 83, 409-420.	1.8	12

#	Article	IF	Citations
127	Reciprocal priming between receptor tyrosine kinases at recycling endosomes orchestrates cellular signalling outputs. EMBO Journal, 2021, 40, e107182.	7.8	12
128	Cyclin-dependent kinase inhibitors and basement membrane interact to regulate breast epithelial cell differentiation and acinar morphogenesis. Cell Proliferation, 2007, 40, 721-740.	5.3	11
129	Are Stem-Like Cells Responsible for Resistance to Therapy in Breast Cancer?. Breast Disease, 2008, 29, 83-89.	0.8	11
130	In vitro antineoplastic activity of C7-substituted mitomycin C analogues MC-77 and MC-62 against human breast-cancer cell lines. Cancer Chemotherapy and Pharmacology, 1992, 29, 290-296.	2.3	10
131	Response and Resistance to the Endocrine Prevention of Breast Cancer. Advances in Experimental Medicine and Biology, 2008, 617, 201-211.	1.6	10
132	Normal Breast Tissue Implanted into Athymic Nude Mice Identifies Biomarkers of the Effects of Human Pregnancy Levels of Estrogen. Cancer Prevention Research, 2009, 2, 257-264.	1.5	8
133	Experimental models of endocrine responsive breast cancer: strengths, limitations, and use. , 2021, 4, 762-783.		8
134	Effect of Berry Extracts and Bioactive Compounds on Fulvestrant (ICI 182,780) Sensitive and Resistant Cell Lines. International Journal of Breast Cancer, 2012, 2012, 1-11.	1.2	7
135	Lack of caveolin-1 (P132L) somatic mutations in breast cancer. Breast Cancer Research and Treatment, 2012, 132, 1185-1186.	2.5	7
136	The Milk Protein Alpha-Casein Suppresses Triple Negative Breast Cancer Stem Cell Activity Via STAT and HIF-1alpha Signalling Pathways in Breast Cancer Cells and Fibroblasts. Journal of Mammary Gland Biology and Neoplasia, 2019, 24, 245-256.	2.7	7
137	Estrogen Deprivation for Breast Cancer Prevention. Recent Results in Cancer Research, 2007, 174, 151-167.	1.8	7
138	Estrogenicity of essential oils is not required to relieve symptoms of urogenital atrophy in breast cancer survivors. Therapeutic Advances in Medical Oncology, 2018, 10, 175883591876618.	3.2	6
139	Epithelial stem cells in the mammary gland: casting light into dark corners. Breast Cancer Research, 1999, 1, 11-3.	5.0	5
140	Stem Cells and Tissue Homeostasis in Mammary Glands. Journal of Mammary Gland Biology and Neoplasia, 2005, 10, 1-3.	2.7	5
141	Biomarker Identification by Knowledge-Driven Multi-Level ICA and Motif Analysis. , 2007, , .		5
142	A new class of small molecule estrogen receptor-alpha antagonists that overcome anti-estrogen resistance. Oncotarget, 2015, 6, 40388-40404.	1.8	4
143	Preparation of a User-Defined Peptide Gel for Controlled 3D Culture Models of Cancer and Disease. Journal of Visualized Experiments, 2020, , .	0.3	4
144	Mutations in DNA damage response genes and breast cancer susceptibility. Breast Cancer Research, 2002, 4, 1.	5.0	3

#	Article	IF	Citations
145	Do early premalignant changes in normal breast epithelial cells predict cancer development?. Breast Cancer Research, 2004, 7, 18-20.	5.0	2
146	Complementary yet distinct roles for oestrogen receptor-Î± and oestrogen receptor-Î² in mouse mammary epithelial proliferation. Breast Cancer Research, 2004, 6, 135-6.	5.0	2
147	Are Stem-Like Cells Responsible for Resistance to Therapy in Breast Cancer?. , 2009, , 97-110.		1
148	Ethnicity influences breast cancer stem cells' drug resistance. Breast Journal, 2018, 24, 701-703.	1.0	1
149	Estrogen Receptor in Mammary Gland Physiology. , 2000, , 1-16.		1
150	New cancer biomarkers deriving from the Early Detection Research Network of NCI/USA. European Journal of Cancer, 2002, 38, S13.	2.8	1
151	The Origin of Estrogen Receptor Î±-Positive and Î±-Negative Breast Cancer. Advances in Experimental Medicine and Biology, 2008, 617, 79-86.	1.6	1
152	Experiments on proliferation of normal human breast tissue in nude mice do not show that progesterone does not stimulate breast cells. Endocrinology, 1996, 137, 1505-1506.	2.8	1
153	Review of: Proliferation of estrogen receptor-alpha-positive mammary epithelial cells is restrained by transforming growth factor-beta1 in adult mice. Breast Cancer Online: BCO, 2006, 9, 1-3.	0.1	0
154	Biomarker identification by knowledge-driven multi-scale independent component analysis. , 2007, , .		0
155	A Systems Biology Approach to Identify Affected Regulatory and Signaling Circuits in Protein Interaction Networks. , 2009, , .		0
156	Hormones and cancer: update from Tokyo 2010. Expert Review of Endocrinology and Metabolism, 2011, 6, 31-33.	2.4	0
157	The seventh ENBDC workshop on methods in mammary gland development and cancer. Breast Cancer Research, 2015, 17, 119.	5.0	0
158	Control of Proliferation in the Normal and Neoplastic Breast. , 2002, , 73-91.		0
159	Abstract B049: An integrated approach to study miRNA involvement in anti-endocrine resistance in breast cancer. , 2013, , .		0
160	Abstract 985: The EurOPDX EDIReX project: Towards a European research infrastructure on patient-derived cancer models. , 2018, , .		0
161	Steroid Receptors, Stem Cells and Proliferation in the Human Breast. , 2008, , 111-121.		0
162	Annotating breast cancer microarray samples using ontologies. AMIA ... Annual Symposium proceedings, 2008, , 414-8.	0.2	0